KennethJayCohenMD

Oncology • Baltimore, MD

Neuro-Oncology

Professor of Oncology and Pediatrics, Johns Hopkins University School of Medicine; Director, Pediatric Neuro-Oncology; Clinical Director Pediatric Oncology; Director, Strategic Partnerships, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile

Already have an account?

Office
1800 Orleans Street
Bloomberg 11N
Baltimore, MD 21287
Phone+1 410-955-8751

Fax+1 410-614-1802

Summary

Dr. Kenneth Cohen is the Clinical Director of Pediatric Oncology and Director of Pediatric Neuro-Oncology at Johns Hopkins in Baltimore, MD. He received his medical degree from SUNY Upstate Medical University and has been in practice 30 years. He specializes in pediatric neuro-oncology and general pediatric oncology. He has more than 80 publications and over 500 citings.

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1991 - 1994
University of ColoradoChief Residency, Pediatrics, 1990 - 1991
University of ColoradoResidency, Pediatrics, 1987 - 1990
SUNY Upstate Medical UniversityClass of 1987

Certifications & Licensure

MD State Medical License 1991 - 2026
PA State Medical License 2024 - 2024
FL State Medical License 2016 - 2018
CO State Medical License 1990 - 1991
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Start of enrollment: 2014 Mar 05
Recruiting
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Start of enrollment: 2017 Apr 04
Terminated
Early Phase 1
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Start of enrollment: 2016 May 01
Completed
Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Combination Therapy for the Treatment of Diffuse Midline Gliomas Start of enrollment: 2021 Oct 20
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study.
Matthias A Karajannis, Arzu Onar-Thomas, Tong Lin, Patricia A Baxter, Daniel R Boué
Neuro-Oncology. 2024-11-19
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
Rishi R Lulla, Allen Buxton, Mark D Krailo, Margot A Lazow, Daniel R Boue
Neuro-Oncology Advances. 2024-03-14
5 citations
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma.
Kenneth J Cohen, Vasu Munjapara, Dolly Aguilera, Robert C Castellino, Stacie L Stapleton
Clinical Cancer Research. 2023-12-15

Press Mentions

WellSpan Health Announces Cancer Partnership with Johns HopkinsJuly 3rd, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/kenneth-cohen